FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161365514> ?p ?o ?g. }

• W2161365514 abstract "Previous studies suggested that estrogen receptor alpha (ERα) plays an important role in the chemoresistance of breast cancers. However, large random trials failed to demonstrate any benefit of the concurrent estrogen antagonist tamoxifen on the chemotherapy efficacy. Thus, in the present study, the importance of the role of ERα in the chemoresistance of breast cancer cells was investigated.The ERα-transfected Bcap37 cells and natural ERα-positive T47D breast cancer cells were treated using chemotherapeutic agents with or without 17-beta estradiol (E2) pretreatment. Their viabilities were assessed using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assays. The dead cell rates were determined using propidium iodide dye exclusion tests, and the expression levels of Bcl-2 and Bax were detected through Western blot analysis. The effects of E2 on the growth of breast cancer cells were also determined via cell growth curve and cell cycle analysis.ERα activation by E2 increased the sensitivity of natural ERα-positive T47D breast cancer cells to chemotherapeutic agents. However, the increase in ERα expression in ERα-negative Bcap37 breast cancer cells also significantly increased their resistance. These phenomena cannot be explained by asserting that ERα mediated the chemoresistance of breast cancer cells by regulating the expression of Bcl-2 and Bax. Our findings show that ERα activation upregulated the expression of Bcl-2 in natural ERα-positive T47D breast cancer cells, whereas ERα activation by E2 downregulated and upregulated the Bcl-2 and Bax expression levels, respectively, in ERα-transfected Bcap37 cells. This phenomenon was due to the influence of ERα on the growth of breast cancer cells. Specifically, ERα activation enhanced the growth of natural ERα-positive breast cancer cells and thus increased their sensitivity to chemotherapeutic agents. However, ERα activation also inhibited the growth of ERα-transfected Bcap37 cells and increased the resistance of cancer cells to chemotherapeutic agents. Chemoresistance of ERα-transfected Bcap37 cells was only due to the specific growth inhibition by E2, which is not applicable to common ERα-positive breast cancer cells.Although ERα was associated with chemoresistance of breast cancers, ERα itself did not mediate this resistance process." @default.
• W2161365514 created "2016-06-24" @default.
• W2161365514 creator A5014351599 @default.
• W2161365514 creator A5019692869 @default.
• W2161365514 creator A5037656487 @default.
• W2161365514 creator A5040843106 @default.
• W2161365514 creator A5057708387 @default.
• W2161365514 creator A5059010780 @default.
• W2161365514 date "2012-05-03" @default.
• W2161365514 modified "2023-10-14" @default.
• W2161365514 title "The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells" @default.
• W2161365514 cites W1591166893 @default.
• W2161365514 cites W1894983360 @default.
• W2161365514 cites W1994039691 @default.
• W2161365514 cites W2000227996 @default.
• W2161365514 cites W2002519450 @default.
• W2161365514 cites W2022602892 @default.
• W2161365514 cites W2025696853 @default.
• W2161365514 cites W2050667900 @default.
• W2161365514 cites W2061291926 @default.
• W2161365514 cites W2073055054 @default.
• W2161365514 cites W2083479280 @default.
• W2161365514 cites W2094718541 @default.
• W2161365514 cites W2096261772 @default.
• W2161365514 cites W2119886876 @default.
• W2161365514 cites W2120398882 @default.
• W2161365514 cites W2124221273 @default.
• W2161365514 cites W2128814059 @default.
• W2161365514 cites W2138605195 @default.
• W2161365514 cites W2164839546 @default.
• W2161365514 cites W2167841373 @default.
• W2161365514 cites W2167926320 @default.
• W2161365514 cites W2183688299 @default.
• W2161365514 cites W2341769195 @default.
• W2161365514 doi "https://doi.org/10.1186/1756-9966-31-42" @default.
• W2161365514 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3474167" @default.
• W2161365514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22553917" @default.
• W2161365514 hasPublicationYear "2012" @default.
• W2161365514 type Work @default.
• W2161365514 sameAs 2161365514 @default.
• W2161365514 citedByCount "29" @default.
• W2161365514 countsByYear W21613655142012 @default.
• W2161365514 countsByYear W21613655142013 @default.
• W2161365514 countsByYear W21613655142014 @default.
• W2161365514 countsByYear W21613655142015 @default.
• W2161365514 countsByYear W21613655142016 @default.
• W2161365514 countsByYear W21613655142017 @default.
• W2161365514 countsByYear W21613655142018 @default.
• W2161365514 countsByYear W21613655142019 @default.
• W2161365514 countsByYear W21613655142020 @default.
• W2161365514 countsByYear W21613655142021 @default.
• W2161365514 countsByYear W21613655142022 @default.
• W2161365514 countsByYear W21613655142023 @default.
• W2161365514 crossrefType "journal-article" @default.
• W2161365514 hasAuthorship W2161365514A5014351599 @default.
• W2161365514 hasAuthorship W2161365514A5019692869 @default.
• W2161365514 hasAuthorship W2161365514A5037656487 @default.
• W2161365514 hasAuthorship W2161365514A5040843106 @default.
• W2161365514 hasAuthorship W2161365514A5057708387 @default.
• W2161365514 hasAuthorship W2161365514A5059010780 @default.
• W2161365514 hasBestOaLocation W21613655141 @default.
• W2161365514 hasConcept C104317684 @default.
• W2161365514 hasConcept C121608353 @default.
• W2161365514 hasConcept C126322002 @default.
• W2161365514 hasConcept C127561419 @default.
• W2161365514 hasConcept C134018914 @default.
• W2161365514 hasConcept C172313692 @default.
• W2161365514 hasConcept C185592680 @default.
• W2161365514 hasConcept C190283241 @default.
• W2161365514 hasConcept C2775934118 @default.
• W2161365514 hasConcept C2777164284 @default.
• W2161365514 hasConcept C2777176818 @default.
• W2161365514 hasConcept C31573885 @default.
• W2161365514 hasConcept C502942594 @default.
• W2161365514 hasConcept C530470458 @default.
• W2161365514 hasConcept C54009773 @default.
• W2161365514 hasConcept C54355233 @default.
• W2161365514 hasConcept C55493867 @default.
• W2161365514 hasConcept C71924100 @default.
• W2161365514 hasConcept C81885089 @default.
• W2161365514 hasConcept C84606932 @default.
• W2161365514 hasConcept C86803240 @default.
• W2161365514 hasConcept C96232424 @default.
• W2161365514 hasConceptScore W2161365514C104317684 @default.
• W2161365514 hasConceptScore W2161365514C121608353 @default.
• W2161365514 hasConceptScore W2161365514C126322002 @default.
• W2161365514 hasConceptScore W2161365514C127561419 @default.
• W2161365514 hasConceptScore W2161365514C134018914 @default.
• W2161365514 hasConceptScore W2161365514C172313692 @default.
• W2161365514 hasConceptScore W2161365514C185592680 @default.
• W2161365514 hasConceptScore W2161365514C190283241 @default.
• W2161365514 hasConceptScore W2161365514C2775934118 @default.
• W2161365514 hasConceptScore W2161365514C2777164284 @default.
• W2161365514 hasConceptScore W2161365514C2777176818 @default.
• W2161365514 hasConceptScore W2161365514C31573885 @default.
• W2161365514 hasConceptScore W2161365514C502942594 @default.
• W2161365514 hasConceptScore W2161365514C530470458 @default.
• W2161365514 hasConceptScore W2161365514C54009773 @default.
• W2161365514 hasConceptScore W2161365514C54355233 @default.
• W2161365514 hasConceptScore W2161365514C55493867 @default.

• next